Important Information for Stemline Investors: Hagens Berman is Investigating Reported Omission of Patient Death One Day Before Stock Offering

SAN FRANCISCO, Feb. 3, 2017 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Stemline Therapeutics, Inc. (NASDAQ: STML) to the firm's investigation into circumstances surrounding reports that a patient died one day before the Company's January 2017 stock offering.

If you purchased or otherwise acquired securities of Stemline before February 2, 2017and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

https://www.hbsslaw.com/cases/STML

or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing STML@hbsslaw.com.

On February 2, 2017, TheStreet published an article entitled "Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money."  TheStreet reported that investors who bought into a $45 million Stemline Therapeutics stock offering on January 19, 2017 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the Company's SL-401 drug.

This news drove the price of Stemline shares down over 34% during intraday trading on February 2, 2017.

"A cancer patient's death occurring from Stemline SL-401 related side effects is a tragic event and is a fact reasonable investors would want to know about," said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Stemline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email STML@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/important-information-for-stemline-investors-hagens-berman-is-investigating-reported-omission-of-patient-death-one-day-before-stock-offering-300401665.html

SOURCE Hagens Berman Sobol Shapiro LLP